Modulating Inflammation for the Treatment of Disease:
Novel Therapeutic Approaches and Modalities
MEETING AGENDA
| 8:00-8:30 | Registration and Coffee |
| 8:30-8:45 | Welcome and opening remarks |
| Morning Session Moderated by Dirk Smith, Cascadia Drug Development Group |
|
| 8:45-9:15 | Mike Wittekind, CEO, Olympic Protein Technologies New developments for extending functionalities of protein therapeutics |
| 9:15-9:45 | Gabriela Hernandez-Hoyos, Senior Director of Immunobiology, Aptevo Therapeutics APVO210: Improving the biological properties of IL-10 for autoimmune and inflammatory diseases through a targeted cytokine bispecific ADAPTIR molecule |
| 9:45-10:15 | Fred Ramsdell, Vice President, Research Parker Institute for Cancer Immunotherapy Neoantigens and immunogenicity in cancer patients |
| 10:15-10:45 | Coffee break and poster viewing |
| 10:45-11:15 | John Babcook, Senior VP, Discovery Research, Zymeworks Inc. AzymtericTM Antibody Platform: Enabling Bispecific Therapeutics |
| 11:15-11:45 | Santanu Bose, Professor, Washington State University, Dept of Veterinary Microbiology and Pathology, College of Veterinary Medicine Therapeutic activity of S100A9 blocking antibody for treatment of influenza A virus associated pneumonia |
| 11:45-1:00 | Lunch and poster viewing (lunch will be provided) |
| Afternoon Session Moderated by Chris Mehlin, Fred Hutchinson Cancer Research Center |
|
| 1:00-1:30 | Chris Mehlin, Director, Peptide Drug Discovery Initiative, FHCRC Simultaneous Multiple Interaction T cell Engaging (SMITE) Bispecifics: Putting some teeth into BiTEs |
| 1:30-2:00 | Lili Cheng, Research Fellow, Protagonist Therapeutics Discovery and preclinical development of PTG-200, an oral peptide antagonist of the IL-23 receptor |
| 2:00-2:30 | Steve Ziegler, Director of Immunology, Benaroya Research Institute |
| 2:30-2:45 | Short break |
| 2:45-3:15 | Wei Yan, Founder and CEO, Sound Biologics Development of MabPair Technology, a Novel Platform for Antibody Combination Therapy |
| 3:15-3:35 | short talk: Mark Bazett, Director, Preclinical and Translational Research, Qu Biologics Site-specific anti-cancer efficacy with bacterial-derived Immunotherapies |
| 3:40-4:00 | Closing remarks |
| 4:00-5:00 | Post meeting reception |
